What is Alzheimer's disease?

Alzheimer's disease is a progressive brain disease caused by the accumulation of two abnormal proteins — beta-amyloid and tau — in and around brain cells. It is the most common cause of dementia, accounting for 60 to 80 percent of all dementia cases. The biological process typically begins decades before symptoms appear. When symptoms do emerge, they usually start with memory loss and progress over 8 to 12 years through loss of language, judgment, function, and ultimately basic abilities.

What causes Alzheimer's disease?

The full cause is not known, but the immediate biology is. Beta-amyloid protein accumulates between neurons, forming plaques. Tau protein accumulates inside neurons, forming tangles. These disrupt neural communication and eventually cause neuron death, particularly in the hippocampus (memory) and other regions. Why this happens is less clear — a combination of genetic risk factors, age-related changes, vascular disease, metabolic factors, and possibly inflammation contributes. A small fraction (1 to 5 percent) is caused by specific inherited gene mutations.

How is Alzheimer's disease diagnosed?

Diagnosis is primarily clinical, based on pattern of symptoms, cognitive testing, and ruling out other causes. A typical workup includes: detailed history from the patient and family, cognitive testing (screening like the MMSE, MoCA, or clock drawing test, often followed by neuropsychological testing), physical and neurological exam, blood work to rule out reversible causes, and brain imaging (MRI). In selected cases, biomarker testing — amyloid PET imaging, cerebrospinal fluid analysis, or newer blood tests — can confirm Alzheimer's pathology definitively. Biomarker-confirmed diagnosis is increasingly important for eligibility for newer disease-modifying therapies.

What are the early signs of Alzheimer's disease?

The most common early sign is memory loss that disrupts daily life — forgetting recent events, repeating the same questions, increasingly relying on notes or family members. Other early signs include difficulty with familiar tasks, confusion about time or date, trouble finding words, changes in mood or personality, and impaired judgment. These build gradually over months to years. A single forgetful moment is normal; a pattern sustained over weeks in a person who didn't previously have it warrants medical evaluation.

How long does Alzheimer's disease last?

Average course from diagnosis to end of life is 8 to 12 years, but individual variation is enormous — some people live 3 years, others more than 20. Time depends on age at diagnosis, overall health, other medical conditions, care quality, and sometimes specific genetic factors. The disease progresses through roughly three clinical stages — early (mild), middle (moderate), and late (severe) — with the middle stage often being the longest.

What treatments are available for Alzheimer's disease?

Two categories. Older symptomatic medications — cholinesterase inhibitors (donepezil, rivastigmine, galantamine) and memantine — provide modest symptomatic benefit for many patients. Newer disease-modifying therapies — lecanemab (Leqembi) and donanemab (Kisunla) — are amyloid-targeting monoclonal antibodies approved since 2023 for early Alzheimer's with confirmed amyloid pathology. They slow progression by about 25 to 35 percent over 18 months in clinical trials but carry real risks including brain swelling and bleeding. Non-medication approaches — exercise, social engagement, structured routine, treatment of coexisting conditions — matter substantially across all stages.

Can Alzheimer's disease be prevented?

Not entirely, but risk can be meaningfully reduced. The 2020 Lancet Commission identified twelve modifiable risk factors that together account for roughly 40 percent of dementia cases — hearing loss, education, traumatic brain injury, hypertension, alcohol use, obesity, smoking, depression, social isolation, physical inactivity, diabetes, and air pollution. Addressing these factors — particularly midlife blood pressure control, hearing loss treatment, physical activity, and avoiding head injuries — reduces lifetime Alzheimer's risk substantially. Family history increases risk but does not eliminate the value of these interventions.

Is Alzheimer's disease hereditary?

A small fraction — about 1 to 5 percent of cases — is caused by specific inherited genetic mutations (in the APP, PSEN1, or PSEN2 genes) that run in families and typically cause young-onset disease before age 65. The majority of Alzheimer's disease is sporadic, without a single inherited cause. Having one parent with late-onset Alzheimer's roughly doubles your lifetime risk compared to someone with no family history, but most children of affected parents do not develop the disease. APOE ε4, a risk gene (not a cause), increases risk but is neither necessary nor sufficient — many carriers never develop Alzheimer's and many non-carriers do.

October 27, 202511 min read

Alzheimer's Disease: A Complete Guide for Patients and Families

Creator: Mai Shimada, MD
Published: Mon Oct 27 2025 00:00:00 GMT+0000 (Coordinated Universal Time)

By Mai Shimada, MD, Emergency medicine-trained physician, Founder of Tokei Health

Alzheimer's disease is the most common cause of dementia and the disease most families picture when they hear the word. This article is a comprehensive physician's guide — what it is biologically, how it presents, how it's diagnosed, what treatments exist, and how to think about living with it. It serves as a hub with links to deeper dives on specific aspects.

If you are looking for something more specific, jump to:

What Alzheimer's disease is

Alzheimer's disease is a progressive brain disease caused by the accumulation of two abnormal proteins in and around brain cells, which gradually disrupts neural communication and leads to neuron death. It was first described by Alois Alzheimer in 1906 in a patient whose brain showed characteristic plaques and tangles at autopsy. The biology has been refined enormously in the intervening century, but the core pathology is the same.

Alzheimer's disease is the most common cause of dementia, accounting for roughly 60 to 80 percent of all dementia cases. An estimated 6.7 million Americans currently live with Alzheimer's; that number is expected to rise significantly as the population ages.

The biology

Two proteins characterize Alzheimer's pathology:

Beta-amyloid accumulates between neurons, forming plaques. These plaques are the earliest pathological change in Alzheimer's disease — they begin to accumulate in the brain decades before symptoms appear. Amyloid PET imaging can now visualize these plaques in living patients, which is how the new amyloid-targeting medications identify candidates.

Tau accumulates inside neurons, forming tangles. Tau pathology correlates more tightly with cognitive symptoms than amyloid does — meaning the amount and location of tau tangles predicts the clinical picture better than amyloid does. Tau spreads through the brain in a specific pattern: starting in the entorhinal cortex (adjacent to the hippocampus), moving into the hippocampus itself, and gradually spreading throughout the cortex.

Other processes contribute: neuroinflammation, synaptic dysfunction, vascular changes, metabolic alterations. But amyloid and tau remain the central pathologies.

The preclinical phase

One of the most important facts about Alzheimer's disease is that the biological disease begins 15 to 20 years before symptoms. A person in their 50s may already have significant amyloid accumulation without any noticeable cognitive changes. By the time memory symptoms are clear, the disease has been underway for decades.

This preclinical phase is a major target of current research. Biomarker-based early detection (blood tests, CSF testing, amyloid PET) can identify people with Alzheimer's pathology before symptoms, though the clinical value of doing so is still being established.

How Alzheimer's disease presents

The typical picture

The classic Alzheimer's presentation starts with memory loss for recent events, progresses over time to include language, judgment, and spatial skills, and eventually affects basic function.

Early signs that are specific enough to warrant evaluation:

Forgetting recent events repeatedly — asking the same question multiple times in the same conversation, not remembering conversations from last week
Difficulty with familiar tasks — a lifelong cook struggling with a familiar recipe
Confusion about time or place — losing track of what day it is, getting lost on familiar routes
Trouble finding words — frequent pauses, substitution of "the thing" for specific nouns
Changes in judgment — uncharacteristic financial decisions, dress inappropriate for weather
Mood or personality changes — apathy, anxiety, irritability that's out of character
Withdrawal from social activities

See our 10 warning signs guide and our how to tell if your parent has dementia post for more specifics.

Atypical presentations

Not everyone with Alzheimer's disease starts with memory loss. A significant minority — particularly younger-onset patients — present atypically:

Posterior cortical atrophy — prominent visual-spatial problems before memory issues
Logopenic primary progressive aphasia — prominent word-finding difficulty
Behavioral or dysexecutive variants — prominent personality or executive function changes, sometimes mistaken for frontotemporal dementia

Specialized testing — often including amyloid PET or CSF biomarkers — is usually needed to confirm Alzheimer's pathology in atypical cases.

Young-onset Alzheimer's

Alzheimer's disease before age 65 — young-onset Alzheimer's — represents about 1 in 20 cases. It is more likely than late-onset disease to be caused by specific inherited gene mutations (APP, PSEN1, PSEN2). Our young-onset dementia post covers this population in detail.

How Alzheimer's disease is diagnosed

Diagnosis is clinical — based on recognizing the pattern — supplemented by testing that rules out other causes and, increasingly, confirms Alzheimer's-specific biology.

The standard workup

Detailed history from the patient and a family member or close friend. Collateral history from someone who knows the person is central — patients often underreport changes.
Cognitive testing. Brief screens (Mini-Cog, clock drawing, MMSE) are a starting point; MoCA is usually done for more detail; full neuropsychological testing is performed in complex cases.
Physical and neurological exam.
Blood work to rule out reversible causes — thyroid function, vitamin B12, folate, complete metabolic panel, sometimes vitamin D, thyroid function.
Brain MRI to rule out stroke, tumor, hydrocephalus, and to assess patterns of atrophy. Hippocampal atrophy supports Alzheimer's.

See our what to do after a low clock drawing test score post for what the typical visit looks like.

Biomarker testing

For patients where diagnosis is unclear or when eligibility for amyloid-targeting treatment is in question, biomarker testing is increasingly used:

Amyloid PET imaging visualizes amyloid plaques directly. A positive scan supports Alzheimer's; a negative scan argues against it.
FDG-PET shows patterns of reduced metabolism characteristic of specific dementias.
Cerebrospinal fluid analysis measures amyloid and tau levels — decreased CSF amyloid and increased CSF tau support Alzheimer's.
Blood-based biomarkers are emerging — plasma p-tau217 and similar tests show promise as less invasive alternatives to CSF and PET.

Biomarker testing is typically coordinated through a neurologist or specialized memory clinic.

Tau PET imaging

A newer imaging test that visualizes tau tangles directly. Because tau pathology correlates more tightly with cognitive symptoms than amyloid, tau PET is particularly useful for tracking disease progression and for clinical trial enrollment.

How Alzheimer's disease progresses

The clinical progression is typically described in three stages — early, middle, and late — though the transitions are gradual and overlapping. Our stages of dementia guide covers these in detail.

Early stage (mild Alzheimer's)

Typically 2 to 4 years. The person is still largely independent but has clearly noticeable memory and functional changes. This is the stage where:

Legal and financial planning should happen while capacity is preserved
Newer disease-modifying therapies (lecanemab, donanemab) may be considered
Cognitive screening and symptomatic medications may be started
Families should establish care teams and support structures

Middle stage (moderate Alzheimer's)

Often the longest stage — 2 to 10 years. Activities of daily living progressively require help. Behavioral symptoms (agitation, sundowning, sometimes wandering) often emerge. Driving is no longer safe. Caregivers often transition from intermittent help to more intensive support or memory care. See our caring for dementia at home guide.

Late stage (severe Alzheimer's)

Typically 1 to 3 years. Limited verbal communication. Full dependence for daily activities. Swallowing difficulties emerge. Comfort-focused care and hospice become central. See our late-stage dementia post.

Treatment

The treatment landscape has changed substantially since 2023 with the approval of the first disease-modifying therapies, though older symptomatic treatments remain important.

Symptomatic medications

Cholinesterase inhibitors (donepezil, rivastigmine, galantamine) and memantine have been the mainstay of Alzheimer's treatment since the 1990s-2000s. They provide modest symptomatic benefit — often described as stabilizing for 6 to 12 months while the underlying disease continues. Many patients notice some benefit; many do not. They are worth a trial in most cases of mild-to-moderate Alzheimer's with reassessment after several months.

See our medications post for details.

Disease-modifying therapies

Lecanemab (Leqembi) and donanemab (Kisunla) are monoclonal antibodies that target amyloid plaques. Approved by the FDA in 2023 and 2024 respectively, they are the first disease-modifying therapies for Alzheimer's disease.

Key facts:

Approved for early Alzheimer's disease (MCI due to AD or mild AD) with confirmed amyloid pathology
Slow clinical decline by approximately 25 to 35 percent over 18 months in clinical trials
Given as IV infusions (lecanemab every 2 weeks, donanemab every 4 weeks)
Require regular MRI monitoring for side effects
Risks include ARIA (amyloid-related imaging abnormalities) — brain swelling and small hemorrhages — which can be severe in a minority of patients
APOE ε4 homozygotes have higher risk of ARIA
Not useful for moderate or severe Alzheimer's, and not useful for non-Alzheimer's dementias

The decision to pursue these therapies should be made with a neurologist who can assess eligibility, risks, and specific clinical picture.

Non-medication approaches

These matter substantially and are sometimes underemphasized:

Physical activity — aerobic exercise has evidence for slowing cognitive decline
Structured routine — reduces anxiety and helps compensate for executive dysfunction
Social engagement — independently associated with better outcomes
Treatment of coexisting conditions — blood pressure, diabetes, depression, sleep apnea, hearing loss
Avoidance of cognitively harmful medications — anticholinergics, benzodiazepines, unnecessary opioids
Cognitive stimulation — reading, puzzles, new skills — evidence for modest benefit

What doesn't help

Coconut oil, medium-chain triglycerides, ketogenic diets — enthusiasm exceeds evidence
Ginkgo biloba, high-dose vitamin E, most other supplements — failed rigorous trials
"Brain games" — improvement on the games themselves, limited real-world transfer
Stem cell therapies marketed for Alzheimer's — not evidence-based, sometimes dangerous

Risk factors

Non-modifiable

Age — the largest risk factor. Alzheimer's risk roughly doubles every 5 years after age 65.
Sex — women have somewhat higher lifetime risk, partly explained by longer life expectancy
Family history — having a first-degree relative with Alzheimer's roughly doubles risk
Genetics — APOE ε4 carrier status modestly to substantially raises risk
Rare autosomal-dominant mutations (APP, PSEN1, PSEN2) — nearly deterministic for affected carriers

Modifiable

The 2020 Lancet Commission identified 12 modifiable risk factors accounting for an estimated 40 percent of dementia cases. The most impactful for Alzheimer's specifically:

Midlife hypertension
Hearing loss (particularly untreated)
Physical inactivity
Obesity in midlife
Diabetes
Depression
Smoking
Traumatic brain injury
Social isolation
Less education
Alcohol use
Air pollution

Our dementia prevention post covers these in detail with actionable guidance.

Genetics

A common source of family anxiety. The short version:

Most Alzheimer's disease is not caused by a single inherited gene
APOE ε4 is a risk gene — it raises risk but does not cause disease. Many carriers never develop Alzheimer's; many non-carriers do
Rare autosomal-dominant mutations (APP, PSEN1, PSEN2) cause about 1-5 percent of Alzheimer's, typically young-onset
Lifetime risk with one affected first-degree relative is roughly double the baseline — about 20 percent vs 10 percent at age 65
Genetic testing is most useful in specific situations (strong family history, young-onset, multigenerational patterns), ideally with genetic counseling

Our is dementia hereditary post covers this in detail.

Living with Alzheimer's disease

For people with an Alzheimer's diagnosis and their families, a few things that consistently matter:

In the early months

Establish care with a clinician who will coordinate long-term
Complete legal and financial planning (power of attorney, advance directives, healthcare proxy)
Have direct family conversations about caregiving, roles, and expectations
Consider disease-modifying therapy eligibility with a neurologist
Begin lifestyle interventions with evidence (exercise, sleep, blood pressure, hearing)
Establish baseline measurements for future comparison

In middle stage

Transition caregiving support as needed — in-home help, adult day programs, memory care when appropriate
Safety-proof the home environment
Focus on symptom management — behavioral approaches before medications
Protect caregiver health with regular respite and support
Coordinate with specialists as needed — particularly for sleep, depression, parkinsonism

In late stage

Consider palliative care and eventually hospice
Focus on comfort — physical, emotional, sensory presence
Make peace with what the disease has taken and stay present with what remains

Our caring for dementia at home post and late-stage dementia post cover these stages in depth.

Resources

Alzheimer's Association helpline — 1-800-272-3900, 24 hours, free. The single most useful number for Alzheimer's questions.
National Institute on Aging — patient resources at nia.nih.gov
Alzheimer's Disease Research Centers (NIH) — specialized academic centers, directory available through NIA
A behavioral neurologist or memory clinic for complex or atypical cases
Genetic counselor if family history or inherited disease is a concern

Related symptoms

References

Alzheimer's Association. 2024 Alzheimer's Disease Facts and Figures. Alzheimer's & Dementia. 2024;20(5):3708–3821.
Jack CR Jr, Bennett DA, Blennow K, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimer's & Dementia. 2018;14(4):535–562.
van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in early Alzheimer's disease. New England Journal of Medicine. 2023;388(1):9–21.
Livingston G, Huntley J, Sommerlad A, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. The Lancet. 2020;396(10248):413–446.
Scheltens P, De Strooper B, Kivipelto M, et al. Alzheimer's disease. The Lancet. 2021;397(10284):1577–1590.

Disclosure: Dr. Shimada is the founder of Tokei Health. This article is informational and is not a substitute for individual medical advice from your own clinician.

Frequently Asked Questions

What is Alzheimer's disease?: Alzheimer's disease is a progressive brain disease caused by the accumulation of two abnormal proteins — beta-amyloid and tau — in and around brain cells. It is the most common cause of dementia, accounting for 60 to 80 percent of all dementia cases. The biological process typically begins decades before symptoms appear. When symptoms do emerge, they usually start with memory loss and progress over 8 to 12 years through loss of language, judgment, function, and ultimately basic abilities.
What causes Alzheimer's disease?: The full cause is not known, but the immediate biology is. Beta-amyloid protein accumulates between neurons, forming plaques. Tau protein accumulates inside neurons, forming tangles. These disrupt neural communication and eventually cause neuron death, particularly in the hippocampus (memory) and other regions. Why this happens is less clear — a combination of genetic risk factors, age-related changes, vascular disease, metabolic factors, and possibly inflammation contributes. A small fraction (1 to 5 percent) is caused by specific inherited gene mutations.
How is Alzheimer's disease diagnosed?: Diagnosis is primarily clinical, based on pattern of symptoms, cognitive testing, and ruling out other causes. A typical workup includes: detailed history from the patient and family, cognitive testing (screening like the MMSE, MoCA, or clock drawing test, often followed by neuropsychological testing), physical and neurological exam, blood work to rule out reversible causes, and brain imaging (MRI). In selected cases, biomarker testing — amyloid PET imaging, cerebrospinal fluid analysis, or newer blood tests — can confirm Alzheimer's pathology definitively. Biomarker-confirmed diagnosis is increasingly important for eligibility for newer disease-modifying therapies.
What are the early signs of Alzheimer's disease?: The most common early sign is memory loss that disrupts daily life — forgetting recent events, repeating the same questions, increasingly relying on notes or family members. Other early signs include difficulty with familiar tasks, confusion about time or date, trouble finding words, changes in mood or personality, and impaired judgment. These build gradually over months to years. A single forgetful moment is normal; a pattern sustained over weeks in a person who didn't previously have it warrants medical evaluation.
How long does Alzheimer's disease last?: Average course from diagnosis to end of life is 8 to 12 years, but individual variation is enormous — some people live 3 years, others more than 20. Time depends on age at diagnosis, overall health, other medical conditions, care quality, and sometimes specific genetic factors. The disease progresses through roughly three clinical stages — early (mild), middle (moderate), and late (severe) — with the middle stage often being the longest.
What treatments are available for Alzheimer's disease?: Two categories. Older symptomatic medications — cholinesterase inhibitors (donepezil, rivastigmine, galantamine) and memantine — provide modest symptomatic benefit for many patients. Newer disease-modifying therapies — lecanemab (Leqembi) and donanemab (Kisunla) — are amyloid-targeting monoclonal antibodies approved since 2023 for early Alzheimer's with confirmed amyloid pathology. They slow progression by about 25 to 35 percent over 18 months in clinical trials but carry real risks including brain swelling and bleeding. Non-medication approaches — exercise, social engagement, structured routine, treatment of coexisting conditions — matter substantially across all stages.
Can Alzheimer's disease be prevented?: Not entirely, but risk can be meaningfully reduced. The 2020 Lancet Commission identified twelve modifiable risk factors that together account for roughly 40 percent of dementia cases — hearing loss, education, traumatic brain injury, hypertension, alcohol use, obesity, smoking, depression, social isolation, physical inactivity, diabetes, and air pollution. Addressing these factors — particularly midlife blood pressure control, hearing loss treatment, physical activity, and avoiding head injuries — reduces lifetime Alzheimer's risk substantially. Family history increases risk but does not eliminate the value of these interventions.
Is Alzheimer's disease hereditary?: A small fraction — about 1 to 5 percent of cases — is caused by specific inherited genetic mutations (in the APP, PSEN1, or PSEN2 genes) that run in families and typically cause young-onset disease before age 65. The majority of Alzheimer's disease is sporadic, without a single inherited cause. Having one parent with late-onset Alzheimer's roughly doubles your lifetime risk compared to someone with no family history, but most children of affected parents do not develop the disease. APOE ε4, a risk gene (not a cause), increases risk but is neither necessary nor sufficient — many carriers never develop Alzheimer's and many non-carriers do.

Take the Clock Drawing Test

A quick, evidence-based screening tool you can take from home in a few minutes.

Start the Clock Drawing Test